Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

Beth Snyder Bulik

Senior Editor

Most COPD patients suffer symptoms daily, but contrary to the typical advice doled out in pharma TV commercials, they’re not talking to their doctors about it. A new Phreesia point-of-care survey finds that fewer than half (44%) of chronic obstructive pulmonary disease (COPD) patients have detailed discussions about symptoms with their doctors.

Meanwhile, two-thirds of patients said COPD has a “substantial impact” on their everyday lives.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Suf­fer­ing in si­lence: COPD pa­tients face fre­quent symp­toms, dis­sat­is­fac­tion with meds, but don't talk to docs — sur­vey

Beth Snyder Bulik

Senior Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Suffering in silence: COPD patients face frequent symptoms, dissatisfaction with meds, but don't talk to docs — survey

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir